JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia

(2016) K Canté-Barrett et al.   LEUKEMIA

Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling

(2016) Geoffrey A Smith et al.   Nature Chemical Biology

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

(2016) Yunlei Li et al.   PLOS MEDICINE

Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis

(2016) Valentino Conter et al.   Lancet Haematology

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia

(2015) R Marke et al.   LEUKEMIA

Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434

(2015) Stuart S. Winter et al.   PEDIATRIC BLOOD & CANCER

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

(2015) Mignon L. Loh et al.   PEDIATRIC BLOOD & CANCER

Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells

(2014) D. Jing et al.   BLOOD

Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003

(2014) Katharine Patrick et al.   BRITISH JOURNAL OF HAEMATOLOGY

Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential

(2014) Louise M. Treanor et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Direct Reversal of Glucocorticoid Resistance by AKT Inhibition in Acute Lymphoblastic Leukemia

(2013) Erich Piovan et al.   CANCER CELL

IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia

(2013) Corey N. Miller et al.   INTERNATIONAL IMMUNOLOGY

Relapsed childhood acute lymphoblastic leukaemia

(2013) Deepa Bhojwani et al.   LANCET ONCOLOGY

BH3 profiling in whole cells by fluorimeter or FACS

(2013) Jeremy Ryan et al.   METHODS

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

(2012) Stephen P. Hunger et al.   JOURNAL OF CLINICAL ONCOLOGY

Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment

(2011) M. Schmitz et al.   BLOOD

IL-7 Contributes to the Progression of Human T-cell Acute Lymphoblastic Leukemias

(2011) A. Silva et al.   CANCER RESEARCH

Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

(2011) Priscila P Zenatti et al.   NATURE GENETICS

Seeing Is Believing: Illuminating the Source ofIn VivoInterleukin-7

(2011) Grace Yoonhee Kim et al.   Immune Network

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study

(2010) Amanda L Cleaver et al.   Molecular Cancer

Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2009) Kirk R. Schultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

(2009) Elaine Coustan-Smith et al.   LANCET ONCOLOGY